Table 4B.
Posttreatment comparison of significant findings by race within treatment groups
| Clinical Measurement | Placebo (n=14) | Resveratrol (n=14) | p | ||
|---|---|---|---|---|---|
| Mean±SD | CI 95% | Mean±SD | CI 95% | ||
| Caucasians (n=6) | Caucasians (n=5) | ||||
| Clamp M | 4.3±1.5 | 2.7–5.9 | 4.9±2.5 | 1.7–8.0 | <0.001* |
| 120 min data 2 h GTT (mg/dl) | 163±26 | 136–191 | 132±24 | 102–162 | 0.001* |
| AUC (mg/dl) | 350±55 | 293–408 | 302±29 | 266–339 | 0.006* |
| Non-Caucasians (n=8) | Non-Caucasians (n=9) | ||||
| Clamp M | 4.2±1.5 | 3.0–5.4 | 4.5±1.4 | 3.4–5.5 | 0.940 |
| 120 min data 2 hGTT (mg/dl) | 179±47 | 140–218 | 143±38 | 114–173 | 0.962 |
| AUC (mg/dl) | 344±75 | 281–405 | 305±49 | 267–343 | 0.376 |
Comparison of the baseline (4A) and posttreatment (4B) glucose tolerance and clamp M data in the Caucasian and noncaucasian group of resveratrol and placebo treated subjects. GTT: Oral
glucose tolerance test, AUC: Area under the curve, SD: Standard deviation, CI: Confidence interval.